Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.

Tens of thousands of people with chronic kidney disease in England could be eligible for treatment with AstraZeneca's SGLT2 inhibitor ... 1 and type 2 diabetes as well as chronic heart failure ...

SGLT2 inhibitors more cardioprotective in older versus younger people despite smaller reduction in HbA1c with older age ...

The role of the kidney in blood glucose-level regulation was until recently underestimated. Renal gluconeogenesis, renal glucose uptake and tubular glucose reabsorption are the three ways of renal ...

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...

SGLT2 inhibitors and DPP4 inhibitors are commonly prescribed for managing type 2 diabetes, a condition that often leads to complications such as kidney disease. Both classes of drugs have demonstrated ...

The study, published in Scientific Reports, suggests that this sodium-glucose cotransporter-2 (SGLT2) inhibitor ... renal function. "Empagliflozin significantly reduced CI-AKI incidence in PCI ...

heart failure, CKD, and premature death, so ocedurenone could have slotted perfectly alongside Novo's semaglutide-based products, which are approved for diabetes, obesity, and cardiovascular risk ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...